Jaume Alijotas Reig Institutions of which they are part Head of group Systemic Diseases Vall Hebron Institut de Recerca Email Jaume Alijotas Reig Email Institutions of which they are part Head of group Systemic Diseases Vall Hebron Institut de Recerca
Research lines Development of the European Registry on Obstetric Antiphospholipid Syndrome (EUROAPS/EUROMAP). The so-called obstetric antiphospholipid syndrome seems to have pathogenic, biologic, therapeutic, and evolution features somehow different from the ones observed in those patients who suffer from "classic" antiphospholipid syndrome. Although experience and scientific evidence seem to support this idea, there is a lack of information that allows us to suggest changes in the classification and/or therapeutic criteria. The European Forum on Antiphospholipid Antibody Syndrome has decided to carry on this project and it has chosen the Vall d'Hebron Hospital as the European Coordinating Centre. Many important Spanish and European hospitals will participate in this multicentric study. IP: Jaume Alijotas Reig Proinflammatory cytokines TNF and IL-6 in cellular senescence. A HUVEC aging model. Cells that are chronically exposed to inflammatory signals are more prone to aging than those which are not exposed to such signals. Human vascular endothelial cell (HUVEC) primary cultures activated with TNF-alpha probably increase the expression of ICAM and VCAM, synthesize ROS, and express senescence markers. It is not known what the principal intracellular pathway is (although it is thought that STAT may play a role) and it is unknown if one or more proinflammatory cytokines are needed to activate NF-KB. We are trying to find out the role that IFN-alpha and/or IL-6 and IL-1B may have on the aging inflammatory phenomena and we aim at detecting the intracellular signal pathways (STAT). We are also working on the characterization of the genes involved in these abnormal biologic responses. IP: Jaume Alijotas Reig Immunological basis and new therapeutic options in severe preeclampsia. Three to five percent of pregnancies are complicated by preeclampsia (PE). PE is a multisystemic-related endothelial dysfunction disorder characterized by hypertension, proteinuria and renal injury. Despite considerable research, its etiology and pathophysiology still remains unclear. Different theories involving many pathways including thrombophilia, immunologic changes, circulating angiogenic /antiangiogenic factors and increased oxidative stress have been related to its pathogenesis. The role played by antiphospholipid antibodies (aPL) is a matter of discussion in PE. Biological evidence of endothelial dysfunction related to PE/FGR has been shown by modified plasma markers including fibronectin, von Willebrand factor and ICAM-1 in a similar manner to that which occurs in aPL-related obstetric complications. We are searching now the role played by different aPL and cofactor antibodies, as well as its relationship with angiogenic /antiangiogenic factors and microparticle number in severe PE. IP: Jaume Alijotas Reig, Elisa Llurba Olivé, Anna Suy Franch Immunological alterations as basis of inmunosenescencein pathological aging. This research line is centered into the study of the role of cross-reactivity among oxidized lipoproteins (oxLDL), antiB2-GP1 and membrane phospholipids, as well as between these complexes and heat shock proteins. We also focus into the role of proinflamatory (IL2 / IL6 / TNFalpha) and anti-inflamatory (IL4 / IL-10) cytokines, as well as with the different activation profiles of TCR and/or CD14 (TLR4) and the role of hormones such as melatonin and the growth hormone. IP: Jaume Alijotas Reig Pagination First page « Previous page ‹ Page 1 Current page 2 Page 3 Next page › Last page » Projects Sulfato de magnesio en pauta continua versus discontinua en la conducta expectante de la preeclampsia grave: ensayo clínico aleatorizado IP: Anna Suy Franch Collaborators: Jaume Alijotas Reig Funding agency: Ministerio Sanidad Funding: 57120 Reference: EC11-474 Duration: 01/01/2012 - 31/12/2018 Sulfato de magnesio en pauta continua versus discontinua en la conducta expectante de la preeclampsia grave: ensayo clínico randomizado IP: Anna Suy Franch Collaborators: Jaume Alijotas Reig, Maria del Mar Goya Canino Funding agency: Instituto de Salud Carlos III Funding: 62012.5 Reference: PI11/00388 Duration: 01/01/2012 - 30/06/2016 GLOBE: Gestación Ligada a Obesidad y al Entorno. Estudio longitudinal multicéntrico de factores de riesgo asociados a la obesidad en el embarazo IP: - Collaborators: Jaume Alijotas Reig, Inés Zulema Calero Fernández, Maite Avilés García Funding agency: Instituto de Salud Carlos III Funding: 135883 Reference: PI10/01367 Duration: 01/01/2011 - 31/12/2014 Heparina de Bajo Peso Molecular (HBPM) para la prevención de complicaciones derivadas de la insuficiencia placentaria en las pacientes de riesgo sin trombofilia: estudio multicéntrico randomizado IP: - Collaborators: Jaume Alijotas Reig, Inés Zulema Calero Fernández, Elisa Llurba Olivé, Josep Perapoch López Funding agency: Ministerio Sanidad Funding: 80000 Reference: EC10-205 Duration: 01/01/2011 - 31/12/2016 Pagination First page « Previous page ‹ Page 1 Current page 2 Page 3 Next page › Last page »
